Nektar falls on short seller report

Nektar Therapeutics Inc. (NASDAQ:NKTR) fell $4.31 to $56.65 on Oct. 1 after short seller Plainview LLC released a report calling the value of the biotech's NKTR-214 zero. Nektar lost more than $740 million in market cap during the session.

The report cited

Read the full 411 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE